Immucell (ICCC) EBIT Margin (2010 - 2026)
Immucell's EBIT Margin was 26.93% in Q2 2026, up 18.09 percentage points from 8.84% a year earlier.
Powered by 
Analysis
Immucell (ICCC) EBIT Margin (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Immucell's EBIT Margin was 9.22% through Jun 30, 2026, up 3.08 percentage points year-over-year; for FY2025, it was 5.97%, up 12.16 percentage points from FY2024.
- EBIT Margin shows a five-year change of +14.96 percentage points (FY2020 to FY2025).
- In earlier years, EBIT Margin was -6.19% in FY2024 (+26.71 pp), -32.90% in FY2023 (-20.52 pp), -12.38% in FY2022 (-13.72 pp) and 1.34% in FY2021 (+10.33 pp).
- The Q2 2026 figure marks the highest quarterly EBIT Margin in data going back to Q2 2010.
- Compared with a year earlier, EBIT Margin was higher in five of the last six quarters, with an average year-over-year change of +13.96 percentage points.
- The best year-over-year quarter for EBIT Margin over five years was Q1 2024 (a gain of 61.32 percentage points); the worst was Q1 2023 (a drop of 74.97 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 28.37% |
| 10 | Immucell | 95.91 Mn | 73.35 Mn | 2.44 Mn | 26.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.93% |
| Dec 31, 2025 | -0.76% |
| Sep 30, 2025 | 0.36% |
| Jun 30, 2025 | 8.84% |
| Mar 31, 2025 | 13.85% |
| Dec 31, 2024 | 8.02% |
| Sep 30, 2024 | -9.56% |
| Jun 30, 2024 | -25.34% |
| Mar 31, 2024 | -4.13% |
| Sep 30, 2023 | -21.94% |
| Jun 30, 2023 | -36.93% |
| Mar 31, 2023 | -65.46% |
| Dec 31, 2022 | -41.77% |
| Sep 30, 2022 | -12.86% |
| Jun 30, 2022 | -16.03% |
| Mar 31, 2022 | 9.51% |
| Dec 31, 2021 | 2.67% |
| Sep 30, 2021 | 5.26% |
| Jun 30, 2021 | 4.74% |
| Mar 31, 2021 | -9.12% |
API Access
Immucell EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=ICCC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "ICCC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=ICCC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();